{"id":"alk3831","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALK3831 is a depot formulation of aripiprazole, a partial dopamine D2/D3 receptor agonist, administered via intramuscular injection to provide extended therapeutic coverage over weeks or months. This extended-release approach aims to improve medication adherence and maintain stable antipsychotic efficacy in patients with schizophrenia or bipolar disorder. The sustained delivery reduces the need for frequent dosing while maintaining consistent plasma levels of the active agent.","oneSentence":"ALK3831 is a long-acting injectable formulation of aripiprazole designed to provide sustained dopamine D2/D3 receptor antagonism for antipsychotic effect.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:24.981Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (maintenance treatment)"},{"name":"Bipolar I disorder (maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT02634346","phase":"PHASE3","title":"A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-12","conditions":"Schizophrenia","enrollment":403},{"nctId":"NCT02804568","phase":"PHASE1","title":"A Phase 1 Safety Study in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-06","conditions":"Schizophrenia","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALK3831","genericName":"ALK3831","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALK3831 is a long-acting injectable formulation of aripiprazole designed to provide sustained dopamine D2/D3 receptor antagonism for antipsychotic effect. Used for Schizophrenia (maintenance treatment), Bipolar I disorder (maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}